Cero Therapeutics Holdings, Inc. filed an 8K report on October 16, 2025, announcing an increase of $500,000 in the initial closing of a Securities Purchase Agreement, raising gross proceeds to approximately $2.25 million for 3,816 shares of Series E Preferred Stock. The total potential funding remains $7 million, with $4.75 million yet to be secured.